Fulgent Genetics price to free cash flow FLGT

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 56.0×; Nov 2024
9-year median: 32.0×
9-year range: 2.7× to 431×
Peer median: 22.8×

Fulgent Genetics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Nov 2024, at 56.0×.

On the days it had one over the last 9 years, its median was 32.0×, from 2.7× in Oct 2022 to 431× in Aug 2019.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	56.0×	31.8×	144×
2023	39.9×	3.1×	41.8×
2022	3.2×	2.7×	4.4×
2021	5.4×	4.4×	29.0×
2020	144×	41.6×	144×
2019	44.5×	35.9×	431×
2018	42.8×	40.9×	55.5×
2017	46.9×	34.9×	46.9×

Against its peers

Companies in Medical - Diagnostics & Research nearest Fulgent Genetics' size, closest first, today.

Company	Price to free cash flow
FLGTFulgent Genetics	n/m
NRCNRC Health	22.4×
ICCCImmucell	22.1×
CDNACareDx	n/m
VCYTVeracyte	23.2×
BLLNBillionToOne	153×
Peer median	22.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Fulgent Genetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.